{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-023352","form_type":"8-K","ticker":"PAVM","cik":"0001624326","company_name":"PAVmed Inc.","filed_at":"2026-05-15T12:05:34+00:00","discovered_at":"2026-05-15T12:10:00.409457+00:00","generated_at":"2026-05-15T12:12:27.220445+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PAVmed Q1 GAAP net loss $7.0M; Lucid Diagnostics revenue $1.3M, 3,177 tests","bullets":["GAAP net loss $7.0M ($4.42 diluted EPS); non-GAAP adjusted loss $1.9M ($1.17 per share).","Cash and equivalents $6.5M at Mar 31, up from $1.5M at Dec 31, 2025.","Lucid Diagnostics Q1 EsoGuard revenue $1.3M, 3,177 tests processed; raised $17M in public offering, proforma cash $45M.","Veris Health advancing implantable physiological monitor towards FDA 510(k) submission.","PAVmed relaunched medical device portfolio including PortIO and Duke-licensed endoscopic imaging."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-023352","json":"https://secwatch.observer/filing/0001493152-26-023352.json","markdown":"https://secwatch.observer/filing/0001493152-26-023352.md","text":"https://secwatch.observer/filing/0001493152-26-023352.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1624326/000149315226023352/0001493152-26-023352-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1624326/000149315226023352/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T12:12:27.220445+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d968d4a99a9a21b2ddc103b1100914c4bc567662","claim":"PAVmed Inc. reported first quarter ended March 31, 2026 results: net income approximately $7.0 million, EPS $(4.42) per common share on a diluted basis.","evidence_excerpt":"On May 15, 2026, PAVmed Inc. (the “ Company ”) issued a press release announcing financial results for its fiscal quarter ended March 31, 2026","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1624326/000149315226023352/0001493152-26-023352-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Net income","value":"approximately $7.0 million"},{"label":"EPS","value":"$(4.42) per common share on a diluted basis"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}